RxDoctor Payments DataLook up a doctor →

Francis Averill, MD

Pulmonary Disease · Clearwater, FLNPI 1629005020

Payments from drug & device makers

$6,250,799in general payments, 2019–2025

Across 2,814 payments — averaging $2221.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$1.7M
  • AstraZeneca$706K
  • Genentech, Inc.$691K
  • E.r. Squibb & Sons, L.L.C.$435K
  • GSK$432K
  • Boehringer Ingelheim$345K
  • plus $2M from 54 others
$52,598in research payments, 2019–2025

Across 19 payments — averaging $2768.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Harmony Biosciences LLC$37K
  • United Therapeutics Corporation$15K
  • Eli Lilly$109

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insmed, Inc.611$1,684,178
AstraZeneca408$705,782
Genentech, Inc.84$691,435
E.r. Squibb & Sons, L.L.C.7$435,398
GSK329$432,266
Boehringer Ingelheim158$344,786
Eli Lilly8$187,254
Kadmon Corporation LLC8$182,506
Hikma Pharmaceuticals USA9$170,954
Takeda Pharmaceuticals U.S.A., Inc.67$161,508
United Therapeutics Corporation106$137,423
Chiesi USA, Inc.41$118,641
Eisai Inc.19$104,319
Paratek Pharmaceuticals, Inc.39$104,125
Teva Pharmaceuticals USA, Inc.37$99,705
Mannkind Corporation18$97,624
Harmony Biosciences LLC103$81,829
Astrazeneca AB4$79,468
Redhill Biopharma Inc.21$72,972
Amgen(2 entities)41$68,541
Astrazeneca UK Limited5$59,146
Dermira, Inc.11$36,505
Hoffmann-la Roche Limited7$35,592
Regeneron16$31,518
Imbrium Therapeutics L.p.17$29,569
Sanofi US Services Inc.12$27,310
Boehringer Ingelheim International GmbH121$26,740
Mylan Specialty L.p.26$15,945
Boehringer Ingelheim France S.a.s.80$9,840
Zevra Therapeutics Inc1$5,718
Olympus Corporation Of The Americas15$2,362
Jazz Pharmaceuticals Inc.58$1,479
Regeneron Healthcare Solutions, Inc.38$1,035
Sanofi26$991
Grifols USA, LLC31$774
Actelion Pharmaceuticals US, Inc.24$745
Mallinckrodt Hospital Products Inc.27$740
Novartis26$562
Bayer24$552
Axsome Therapeutics, Inc.14$307
Watermark Medical, Inc.1$280
Idorsia Pharmaceuticals US Inc19$242
Electromed, Inc.17$204
Genentech USA, Inc.11$195
Inspire Medical Systems, Inc.4$194
Abbott3$191
Merck6$148
Philips North America LLC6$144
ANI Pharmaceuticals, Inc.5$132
Covis Pharma GmbH5$115
Pulmonx Corporation2$111
Sunovion Pharmaceuticals Inc.5$105
Verona Pharma, Inc.4$101
Circassia Inc.6$75
Inogen, Inc.5$58
Advanced Respiratory, Inc3$47
Sanofi-aventis U.S. LLC2$45
Pharming Healthcare, Inc.2$43
3b Medical, Inc.2$33
Vapotherm Inc1$25

How this compares

$6,250,799 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida →

Medicare billing

Part B allowed, 2024
$263,779
Medicare patients
692
Services billed
3,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Clearwater

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →